Compared to traditional immunomodulatory therapies, new biologic therapeutics for gMG have more specific target engagement via blockade of immunoglobulin G recycling via the neonatal Fc receptor (FcRn; such as efgartigimod, rozanolixizumab) or inhibition of complement activation (such as eculizumab, ravulizumab, zilucoplan). Phase 3 trials with each of these agents have shown rapid clinical improvement and good safety and tolerability. As a result, a paradigm shift away from nonspecifically targeted therapies is upon us. It is early in this new era to compare outcomes with FcRn inhibition vs complement inhibition, but at present, the former is in much broader clinical use owing largely to economic considerations by payors. This current state of affairs warrants education of HCPs who provide care to patients with gMG on the data supporting the use of FcRn blockers, longer-term outcomes with these agents, patient selection, dose management, and—while we await guidelines updates--on a reconsideration of the sequencing of therapeutic options for the management of gMG.
MG and other neuromuscular disease specialists, neuroimmunologists, general neurologists, other physicians, specialty and hospital pharmacists, and NPs and PAs who manage patients with MG
Understand the mechanism of action of FcRn blockers AChR-Ab+ gMG and review foundational clinical trial data
Analyze recent secondary analyses of clinical trials and reported experience with incorporation of FcRn blockers into gMG management
Review recently reported safety experience and patient selection processes for incorporation of FcRn blockers into gMG management
Plan implementation of therapy with appropriate selection of patients for individualized management of generalized MG by the interprofessional team at the host center
Welcome and Introductions - James F. Howard Jr., MD
Pathophysiology of gMG and Explanation of Why FcRn Receptor is a Therapeutic Target - James F. Howard Jr., MD
Clinical Trial Data and Follow-On Extension Data for FcRn Receptor Blockers: Efficacy and Safety - James F. Howard Jr., MD and Nicholas J. Silvestri, MD
Individualizing Care Plans for Patients with gMG: When and How to Use FcRn Blockers - Nicholas J. Silvestri, MD
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| James F. Howard Jr., MD | Consultant/Advisor: Alexion Pharmaceuticals; argenx; Avilar Therapeutics; EMD Serono Inc.; F. Hoffmann La Roche; Horizon Therapeutics; Merck & Co., Inc.; NMD Pharma; Novartis Pharmaceuticals; Regeneron Pharma; Sanofi; Seismic Therapeutics; Toleranzia AB; UCB Bioscience Grant/Research Support: Ad Scientiam; Alexion Pharmaceuticals; argenx; Cartesian Therapeutics; The Centers for Disease Control & Prevention; NMD Pharma; Patient-Centered Outcomes Research Institute; UCB Bioscience |
| Nicholas J. Silvestri, MD, FAAN | Consultant/Advisor: Alexion Pharmaceuticals; argenx; Immunovant, Inc.; Janssen Pharmaceuticals; Takeda Pharmaceuticals; UCB Bioscience Speaker's Bureau: argenx; Alexion Pharmaceuticals; Immunovant, Inc.; UCB Bioscience |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from argenx.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and argenx do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
